Abstract
EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
